KRONOS BIO INC. - COMMON STOCK

0,9564

10-января-25 15:45:00

15 мин. задержка

Акции

-0,0286

-2,90%

Сегодняшний диапазон

0,9260 - 0,9809

ISIN

N/A

Источник

NASDAQ

Kronos Bio Announces CEO Transition and Reduction in Force

27 ноя 2024 06:30:00 Источник Nasdaq GlobeNewswire
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

14 ноя 2024 15:02:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

13 ноя 2024 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

05 ноя 2024 08:00:01 Источник Nasdaq GlobeNewswire
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

23 окт 2024 07:55:00 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

09 окт 2024 07:55:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

07 окт 2024 07:55:00 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

25 сен 2024 07:55:00 Источник Nasdaq GlobeNewswire
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

23 сен 2024 07:55:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Medical and Investor Conferences in September

03 сен 2024 07:55:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update

08 авг 2024 15:15:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

23 июл 2024 15:15:00 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 май 2024 16:15:00 Источник Nasdaq GlobeNewswire
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

22 май 2024 15:30:00 Источник Nasdaq GlobeNewswire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

21 май 2024 07:15:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports First-Quarter 2024 Financial Results

09 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 15:01:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

21 мар 2024 06:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

07 мар 2024 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

05 мар 2024 15:44:11 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.